S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia Early Because of Positive Risk-Benefit (2013/10/9)|
|Gilead’s Idelalisib Significantly Reduces Rate of Disease Progression or Death in Phase 3 Chronic Lymphocytic Leukemia Study (2013/11/18)|
|Emergent BioSolutions Announces Acceptance of Otlertuzumab Abstracts for Presentation at 2013 American Society of Hematology Annual Meeting (2013/11/7)|
|TG Therapeutics, Inc. Initiates First Combination Clinical Trial of TG-1101 and TGR-1202 in Patients With Relapsed and/or Refractory CLL and NHL (2013/11/25)|
|Pharmacyclics Reports Second Quarter 2013 Results (2013/7/31)|
|Infinity Reports Second Quarter 2013 Financial Results and Provides Company Update (2013/8/8)|
|Pharmacyclics Reports Third Quarter 2013 Results (2013/11/7)|
|Gilead to Present Data on Oncology Pipeline at American Society of Hematology Annual Meeting (2013/11/7)|
|Initial Phase III Results of the FIRST® Trial (MM-020/IFM 07 01) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (PTS) Ineligible for Stem Cell Transplantation (SCT) Accepted for Plenary Presentation at ASH Annual Meeting (2013/11/7)|
|New Drug Application Filing for Ibrutinib Accepted in Two B-cell Malignancies by the U.S. FDA ()|
Click above to view more mutual fund data and stats for cll - Connacher Oil and Gas Limited.